Tag:
Ablynx
Latest Headlines
Latest Headlines
Hot Ablynx antibody tech earns $69M discovery pact with Merck Serono
Just days after a rapidly downsizing Pfizer offloaded a partnership with Belgium's Ablynx on its hot nanobody technology, Merck Serono has stepped up to the plate with a fresh $28 million upfront
Pfizer dumps rights to RA drugs from biotech Ablynx
Belgian biotech Ablynx took a hit this morning after Pfizer ( $PFE ) let go of its rights to the smaller firm's nanobody compounds for treating rheumatoid arthritis. Pfizer dumped the program as part
Nanobody selected for Alzheimer's treatment development
Boehringer Ingelheim has selected a nanobody lead candidate from Ablynx for further development in the treatment of Alzheimer's disease. This is the first lead candidate emerging from the Alzheimer's
Tiny antibodies could beat out blockbusters
Antibodies have provided some of biotech's biggest blockbusters. But they have a distinct limitation. They are big, complex and rather fragile. Scientists, though, are now studying the small
Ablynx extends R&D pact with Novartis
Belgium's Ablynx says it has agreed to extend its research collaboration with Novartis for another year. The two are exploring nanobodies, which are smaller than antibodies but easier to use.
Ablynx gains partner in $340M nanobody deal
Belgium's Ablynx is pocketing $14.5 million (€10 million) from Merck Serono as a down payment for their new collaboration to find new 'nanobodies' for oncology and immunology. The milestones are
C&L: Bioxel CEO resigns
Bioxel Pharma has announced the resignation of Pascal Delmas as president and CEO. Bioxel also appointed Thomas Warden as vice-president, sales, marketing and regulatory affairs. Denmark's Lundbeck
ALSO NOTED: Ablynx pockets upfront fee; Plexxikon publishes cancer data; Solvay drug on fast track; and much more...
> Belgium's Ablynx says it has received an undisclosed milestone payment from Novartis for an exclusive license for a program involved in their alliance on therapeutic nanobodies.
ALSO NOTED: Pfizer to buy CovX; Florida commits $94M to Max Planck; Affymetrix buys USB; HGS touts animal trial results for ant
> Aggressively looking to expand its role in biologics, Pfizer has struck a deal to buy CovX. No figures were given.
Boehringer, Ablynx team up on nanobodies
Boehringer Ingelheim must be happy with its previous partnership  with Ablynx.
